Home / Research library / PE-22-28
PE-22-28: molecular data, studies & sources
PE-22-28 is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
Molecular record not yet resolved
A sufficiently specific molecular record was not resolved for this name. Formula, molecular weight and structure are withheld until the exact sequence, salt or preparation can be verified.
MF: not assigned · MW: not assigned · Structure: not assigned
Registered clinical trials
Studies registered on ClinicalTrials.gov that list PE-22-28 as an intervention. Studies that only measure the molecule as a biomarker, or use it only as a comparator or background arm for another drug, are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.
No registered study naming this compound was matched. This is a documented gap in registry coverage, not proof that no study exists.
Registry check 2026-10-01 · Run this search on ClinicalTrials.gov
Human intervention studies
Selected studies in which participants received PE-22-28, with their indexed or reviewed study type. Check the original article for the formulation, population and controls. Studies that only measured the molecule, or used it as a comparator, are listed separately below and are not counted as intervention studies.
No human study that administered this compound was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Preclinical / laboratory research
Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity.
Djillani A, Pietri M, Moreno S et al. · Frontiers in pharmacology · 2017
PMID 28955242 · DOI: 10.3389/fphar.2017.00643
PE-22-28 supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
PE-22-28 for sale: compare prices, sizes and forms from every tracked supplier →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Amino USAUSD | 10mg Vial1 recorded offers | 10mg Vial · $50.00Checked Nov 6, 2026Supplier listing, PE-22-28 10mg Vial, Amino USA, opens in a new tab |
| Cenexa LabsUSD | 10mg Vial1 recorded offers | 10mg Vial · $76.99Checked Nov 6, 2026Supplier listing, PE-22-28 10mg Vial, Cenexa Labs, opens in a new tab |
| American PeptidesUSD | 10mg Vial1 recorded offers | 10mg Vial · $70.00Checked Nov 6, 2026Supplier listing, PE-22-28 10mg Vial, American Peptides, opens in a new tab |
Reference sources & further reading
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Adalank Spray
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Adamax
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Adamax 1032 Spray
Molecular identity needs further verification
Source verification pending
0 selected publications · 0 human intervention studies
Agomelatine Powder
C15H17NO2
243.30 g/mol · PubChem CID 82148
8 selected publications · 5 human intervention studies · 19 registered trials
Small molecule · highest stage: Approved in at least one jurisdiction (ChEMBL phase 4)
Cerebrolysin
Molecular identity needs further verification
7 selected publications · 5 human intervention studies · 40 registered trials
Dihexa
C27H44N4O5
504.7 g/mol · PubChem CID 129010512
2 selected publications · 0 human intervention studies